Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX1 | P09601 | 2/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979561 | 0.84 | CYP19A1 (0.59) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL10197408 | 0.81 | HMOX1 (0.91) | HMOX1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL10816487 | 0.81 | HMOX1 (0.91) | HMOX1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6979413 | 0.81 | CYP19A1 (0.55) | HMOX1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL11467460 | 0.80 | HMOX1 (0.54) | HMOX1CYP19A1CYP11B1CYP11B2MAPK1 | |
| SCHEMBL11701649 | 0.80 | HMOX1 (0.64) | HMOX1CYP19A1CYP11B1CYP11B2MAPK1 | |
| SCHEMBL9996056 | 0.78 | HMOX1 (1.00) | HMOX1CYP19A1 | |
| SCHEMBL27956563 | 0.78 | HMOX1 (0.62) | HMOX1CYP19A1CYP11B1CYP11B2 | |
| Brolaconazole SCHEMBL2107423 | 0.77 | HMOX1 (0.61) | HMOX1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6971161 | 0.77 | CYP11B1 (0.56) | HMOX1CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | HMOX1 2995/4885CYP19A1 1823/4885CYP11B1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.